Ultime notizie per Cormedix (NASDAQ:CRMD) Azioni

Cormedix

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Cormedix Inc

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and raises the price target from $10 to $18.

News

Price Target

Analyst Ratings

CRMD

Needham Maintains Buy on Cormedix, Raises Price Target to $18

<h3>Gainers</h3>
<ul>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 106.1% to $4.18 during Wednesday's regular session. The market value of their outstanding shares is at $4.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 51.76% to $0.63. The company's market cap stands at $9.3 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock rose 35.29% to $1.34. The company's market cap stands at $58.8 million. </li>
<li>Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) stock rose 33.25% to $53.46. The company's market cap stands at $2.4 billion. The company's, Q3 earnings came out today. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 32.83% to $14.27. The company's market cap stands at $309.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares rose 31.66% to $5.17. The company's market cap stands at $55.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock decreased by 37.0% to $0.2 during Wednesday's regular session. The company's market cap stands at $2.0 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) stock declined by 25.56% to $22.93. The company's market cap stands at $692.4 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined by 20.46% to $6.75. The market value of their outstanding shares is at $411.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) shares decreased by 20.14% to $24.36. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares declined by 15.32% to $10.98. The market value of their outstanding shares is at $613.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares decreased by 15.06% to $18.89. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ANAB

APDN

CALC

CVRX

ENSC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OMCL

OPCH

SAGE

THAR

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

CorMedix shares are trading lower. The company reported Q3 financial results.

Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.14) by 64.29 percent. The company reported quarterly sales of $11.456 million which beat the analyst consensus estimate of $10.839 million.

Earnings

Earnings Beats

Earnings Misses

Cormedix Q3 2024 GAAP EPS $(0.05) Beats $(0.14) Estimate, Sales $11.456M Beat $10.839M Estimate

Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-10-30. Here's what investors need to know before the announcement.
Analysts estimate that Cormedix will report an earnings per share (EPS) of $-0.10. 
Cormedix bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 2.54% drop in the share price the following trading session.
Here's a look at Cormedix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.25</td>
<td>-0.28</td>
<td>-0.20</td>
<td>-0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.25</td>
<td>-0.25</td>
<td>-0.26</td>
<td>-0.17</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-4.0%</td>
<td>14.000000000000002%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730228580_0.png" alt="eps graph" />
<h3>Tracking Cormedix's Stock Performance</h3>
Shares of Cormedix were trading at $13.59 as of October 28. Over the last 52-week period, shares are up 282.91%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRMD/earnings">To track all earnings releases for Cormedix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Cormedix

This retrospective analysis, using data from the Premier Healthcare Database, evaluated hospital admissions from 2020 to 2022 to examine the demographics, clinical characteristics, and outcomes of adult HD-CVC patients hospitalized for bloodstream infections (BSIs). Among the 91,448 unique patients admitted, 25% (N=22,902) presented with a BSI. Key findings include:
<ul>
<li>Patient Demographics: The patient population was 58.2% white, 27.1% black, and 56.6% male, with 59.3% aged 60 years or older. A substantial number of patients lived in vulnerable communities, with 47% residing in the most socioeconomically disadvantaged quartile of neighborhoods nationwide. &nbsp;</li>
<li>Hospitalization Outcomes: The median length of stay for BSI-related hospitalizations was 16 days, with 53.8% of admissions involving time in the ICU (median stay: 8 days). The study reported an all-cause in-hospital mortality rate of 10.3%. &nbsp;</li>
<li>Comorbidities: Patients had extensive comorbidities, with 87.8% having three or more Charlson comorbidity conditions, and 42.6% had six or more. 
<ul>
<li>Economic Impact: The median total cost of admission was $157,000, with $65,000 attributed to ICU care alone. Healthcare utilization, including readmissions (26.8% within 90 days), placed a significant financial burden resulting from these infections.</li>
</ul>
</li>
</ul>

Biotech

Events

General

CorMedix Presents New Data At ASN Kidney Week 2024

Truist Securities analyst Joon Lee maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and raises the price target from $12 to $17.

Truist Securities Maintains Buy on Cormedix, Raises Price Target to $17

<a href="https://www.globenewswire.com/Tracker?data=mJMI1wXjTiLVjAaKtBtErdaaLORG5GnaJDRMThP7iFOr0Cda8jOfSWuJoPr43z3POchq4C2lLi1l67goDbtpWQ==">CorMedix Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-five mid-sized dialysis operator for the supply of DefenCath&#xAE; (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 200 outpatient dialysis clinics located across the United States.
CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15, 2024. Outpatient reimbursement of DefenCath from the Center for Medicare &amp; Medicaid Services (CMS) took effect on July 1st, and CorMedix subsequently commenced the shipment of orders to outpatient dialysis facilities in July. CorMedix anticipates shipments for DefenCath under this agreement to begin in the fourth quarter.

CorMedix Entered Into A New Commercial Supply Contract With A Top-Five Mid-Sized Dialysis Operator For The Supply Of DefenCath

<a href="https://www.globenewswire.com/Tracker?data=IOZSQF7l2NlW9dojiDWx9HMQptoABpF2Il4ywCXA5XTPitneEGZNU0z2MWDTAUvxuelopl_woOJhmiPtw5Rn-w==">CorMedix Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-tier mid-sized dialysis operator for the supply of DefenCath&#xAE; (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 250 outpatient dialysis clinics located across the United States. &nbsp;
CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15, 2024. Outpatient reimbursement of DefenCath from the Center for Medicare &amp; Medicaid Services (CMS) took effect on July 1st, and CorMedix subsequently commenced the shipment of orders to outpatient dialysis facilities in July. CorMedix anticipates shipments for DefenCath under this agreement to begin in the beginning of the fourth quarter.

CorMedix Inc. Announces New Commercial Agreement To Provide Access To DefenCath For Adult Patients With Kidney Failure Receiving Hemodialysis Through A Central Venous Catheter At More Than 250 Outpatient Dialysis Clinics Located Across The United States

CorMedix shares are trading higher after the company on Monday entered into a multi-year commercial supply contract with a healthcare company for the supply of DefenCath to its U.S. facilities.

Shares of CorMedix (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crmd#NASDAQ">CRMD</a>) have been struggling lately and have lost 7.7% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.
The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this pharmaceutical and medical device company enhances its prospects of a trend reversal.
<img alt="1-month candlestick chart for CRMD" class="chart" src="https://staticx-tuner.zacks.com/images/articles/charts/yseop/550/CRMD_Hammer.jpeg" style="height:auto; width:100%" title="" />
<h2>What is a Hammer Chart and How to Trade It?</h2>
This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a &#39;hammer.&#39;
In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day&#39;s close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.
When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.
Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.
Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.
<h2>Here&#39;s What Makes the Trend Reversal More Likely for CRMD</h2>
An upward trend in earnings estimate revisions that CRMD has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. That&#39;s because empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
The consensus EPS estimate for the current year has increased 31% over the last 30 days. This means that the Wall Street analysts covering CRMD are majorly in agreement about the company&#39;s potential to report better earnings than what they predicted earlier.
If this is not enough, you should note that CRMD currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market.
Moreover, a Zacks Rank of 2 for CorMedix is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company&#39;s prospects are beginning to improve.
<a href="https://www.zacks.com/stock/news/2333463/here-s-why-cormedix-crmd-is-a-great-buy-the-bottom-stock-now?cid=CS-BENZ-FT-tale_of_the_tape|hammer_chart_pattern_(ta)-2333463">To read this article on Zacks.com click here.</a>

Technicals

Small Cap

Markets

Trading Ideas

Here's Why CorMedix Is a Great 'Buy the Bottom' Stock Now

<a href="https://www.globenewswire.com/Tracker?data=jmWKlmzWclHPkxouFC8ycS6Eer4tcenbr72FFQ2TkhrRix0wLIPfThWEricnJD1ty7ULlSJd4yf_wf5iLtmUFA==">CorMedix Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a global healthcare company for the supply of DefenCath&#xAE; (taurolidine and heparin) to its facilities in the US. &nbsp;
The company, which provides healthcare services to more than 2,000 clinics in the United States, expects to initially target the utilization of DefenCath in up to 4,000 patients nationally, that would be prioritized based upon medical need. CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15, 2024. Outpatient reimbursement of DefenCath from the Center for Medicare &amp; Medicaid Services (CMS) took effect on July 1st, and CorMedix subsequently commenced the shipment of orders in July. CorMedix anticipates shipments for DefenCath under this agreement to begin in the fourth quarter.

CorMedix Has Entered Into A Multi-Year Commercial Supply Contract With A Global Healthcare Company For The Supply Of DefenCath To Its Facilities In The U.S.

CorMedix shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $13 price target.

U.S. stocks were mostly higher, with the Dow Jones index gaining around 150 points on Monday.
Shares of Galapagos NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) rose sharply during Monday's session after Ecor1 Capital reported a 9.9% stake in the company.
Galapagos shares jumped 10% to $28.47 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares gained 14.3% to $8.22.</li>
<li>MoneyLion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) gained 9.4% to $47.41 after announcing a $20 million share repurchase program.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) jumped 9% to $14.00.</li>
<li>PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) rose 8% to $23.87.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) gained 7% to $5.61.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares rose 6.1% to $7.44 after disclosing that its CEO had acquired over 2 million shares of the company.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) jumped 5.7% to $7.32.</li>
<li>Chart Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NASDAQ">GTLS</a>) gained 5.6% to $130.54.</li>
<li>Rocket Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) jumped 5.5% to $19.63.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) gained 5.3% to $5.95. Rodman &amp; Renshaw analyst Brandon Folkes initiated coverage on Cormedix with a Buy rating and announced a price target of $13.</li>
<li>Pharming Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) gained 5% to $7.98.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) rose 4.8% to $128.95.</li>
<li>ProFrac Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) gained 4.6% to $6.80.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40550998/top-3-financials-stocks-that-could-blast-off-this-quarter">Top 3 Financials Stocks That Could Blast Off This Quarter</a></li>
</ul>

Intraday Update

ACDC

ARRY

CMPS

ENPH

GLPG

GTLS

GYRE

LUNR

PHAR

PRTC

RCKT

XPEV

Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday

Rodman &amp; Renshaw analyst Brandon Folkes initiates coverage on Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy rating and announces Price Target of $13.

Initiation

Rodman & Renshaw Initiates Coverage On Cormedix with Buy Rating, Announces Price Target of $13

RBC Capital analyst Gregory Renza reiterates Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Outperform and maintains $9 price target.

Reiteration

RBC Capital Reiterates Outperform on Cormedix, Maintains $9 Price Target

Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and maintains $10 price target.

Needham Reiterates Buy on Cormedix, Maintains $10 Price Target

CorMedix shares are trading higher. The company reported Q2 financial results.

Cormedix Q2 2024 GAAP EPS $(0.25), Inline, Sales $806.119K Miss $1.674M Estimate

Truist Securities analyst Joon Lee maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and lowers the price target from $14 to $12.

Truist Securities Maintains Buy on Cormedix, Lowers Price Target to $12

CorMedix GAAP EPS of -$0.05 beats by $0.05, revenue of $11.46M beats by $0.62M

Reports Q3 revenue $11.456M, consensus $10.84M. Joe Todisco, CorMedix (CRMD) CEO, commented, "I am excited about the Company's recent progress as w...

CorMedix reports Q3 EPS (5c), consensus (10c)

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Cormedix (CRMD – Research Report) and keeping the price target at $19.00. Jason...

Strong Buy Recommendation for Cormedix Amid DefenCath's Promising Market Trajectory and Strategic Partnerships

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Alphabet (GOOGL) reported upbeat Q3 re...

Alphabet, AMD report Q3 earnings beats: Morning Buzz

CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript

Cormedix (CRMD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham...

Cormedix's Growth Prospects Justify Buy Rating Despite Market Pressures

Cormedix Inc. ( ($CRMD) ) has realeased its Q3 earnings. Here is a breakdown of the information Cormedix Inc. presented to its investors. CorMedix ...

CorMedix Inc. Reports Q3 2024 Financial Results

Truist Financial analyst Les Sulewski assigned a Buy rating to the stock today. The company's shares closed yesterday at $10.05. Sulewski covers th...

Truist Financial Gives a Buy Rating to Cormedix (CRMD)

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Smaller Cap Biotechs Are In Season: How Are We Doing?

Stock Picks From Seeking Alpha's October 2024 New Analysts

AAPL

ABBV

ACGL

ACGLN

ACGLO

ADPT

AMCX

AMPS

APOG

ASOMF

ASOMY

ASPI

ATZAF

AVRE

BHPLF

BILL

BWXT

CIVI

CIVII

CIVIW

CONY

CPRX

CRSP

CSGP

DGEAF

DOCMF

DRMTY

FSLR

GILD

GOOG

GOOGL

GRMN

HRTG

ILMN

JNPR

JVTSF

LOTBY

MSTR

NRDS

NTRA

NVAX

OPINL

PSEC

QDEL

QRVO

RDDT

REGCO

REGCP

SHOP

SMCI

SNAP

TALK

TALKW

TGHLF

TMCWW

TSMWF

VCEL

VCYT

VRTX

XERS

Press Releases

CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024

CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update

Contracts

CorMedix Inc. Announces New Commercial Agreement

CorMedix Inc. to Present at the Cantor Global Healthcare Conference

Health Care

CorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator

CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024

CorMedix Inc. Announces New Data at ASN Kidney Week 2024

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

Comments

Cormedix

Notizie

Ultime notizie per Cormedix (NASDAQ:CRMD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO